- Home
- AORT
AORT
Artivion Inc.
as of 02-27-2026 3:52pm EST
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
| Founded: | 1984 | Country: | United States |
| Employees: | N/A | City: | KENNESAW |
| Market Cap: | 2.1B | IPO Year: | 1996 |
| Target Price: | $48.76 | AVG Volume (30 days): | 461.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | semi-annual |
| EPS: | 0.21 | EPS Growth: | 165.62 |
| 52 Week Low/High: | $21.97 - $48.25 | Next Earning Date: | 05-15-2026 |
| Revenue: | $298,836,000 | Revenue Growth: | 18.01% |
| Revenue Growth (this year): | 13.95% | Revenue Growth (next year): | 11.16% |
| P/E Ratio: | 181.05 | Index: | N/A |
| Free Cash Flow: | 839.0K | FCF Growth: | -92.41% |
AI-Powered AORT Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Artivion Inc. (AORT)
SVP, Clinical & MD Affair
Avg Cost/Share
$35.69
Shares
1,259
Total Value
$44,937.49
Owned After
41,921
SEC Form 4
VP, Chief Accounting Officer
Avg Cost/Share
$35.69
Shares
830
Total Value
$29,625.19
Owned After
127,497
SEC Form 4
SVP, General Counsel
Avg Cost/Share
$35.69
Shares
1,668
Total Value
$59,535.92
Owned After
152,203
SEC Form 4
President & CEO
Avg Cost/Share
$35.69
Shares
13,936
Total Value
$497,417.65
Owned After
766,095
SEC Form 4
Chief Commercial Officer
Avg Cost/Share
$35.69
Shares
2,075
Total Value
$74,062.97
Owned After
188,868
SEC Form 4
EVP, COO, CFO & Treasurer
Avg Cost/Share
$35.69
Shares
4,485
Total Value
$160,083.10
Owned After
143,965
SEC Form 4
SVP, Clinical & MD Affair
Avg Cost/Share
$37.59
Shares
2,423
Total Value
$91,075.72
Owned After
41,921
SEC Form 4
VP, Chief Accounting Officer
Avg Cost/Share
$37.59
Shares
1,731
Total Value
$65,064.83
Owned After
127,497
SEC Form 4
SVP, General Counsel
Avg Cost/Share
$37.59
Shares
3,079
Total Value
$115,733.45
Owned After
152,203
SEC Form 4
President & CEO
Avg Cost/Share
$37.59
Shares
20,962
Total Value
$787,919.66
Owned After
766,095
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Stanton Marshall S. | AORT | SVP, Clinical & MD Affair | Feb 24, 2026 | Sell | $35.69 | 1,259 | $44,937.49 | 41,921 | |
| Horton Amy | AORT | VP, Chief Accounting Officer | Feb 24, 2026 | Sell | $35.69 | 830 | $29,625.19 | 127,497 | |
| Holloway Jean F | AORT | SVP, General Counsel | Feb 24, 2026 | Sell | $35.69 | 1,668 | $59,535.92 | 152,203 | |
| Mackin James P | AORT | President & CEO | Feb 24, 2026 | Sell | $35.69 | 13,936 | $497,417.65 | 766,095 | |
| Davis John E | AORT | Chief Commercial Officer | Feb 24, 2026 | Sell | $35.69 | 2,075 | $74,062.97 | 188,868 | |
| Berry Lance A | AORT | EVP, COO, CFO & Treasurer | Feb 24, 2026 | Sell | $35.69 | 4,485 | $160,083.10 | 143,965 | |
| Stanton Marshall S. | AORT | SVP, Clinical & MD Affair | Feb 23, 2026 | Sell | $37.59 | 2,423 | $91,075.72 | 41,921 | |
| Horton Amy | AORT | VP, Chief Accounting Officer | Feb 23, 2026 | Sell | $37.59 | 1,731 | $65,064.83 | 127,497 | |
| Holloway Jean F | AORT | SVP, General Counsel | Feb 23, 2026 | Sell | $37.59 | 3,079 | $115,733.45 | 152,203 | |
| Mackin James P | AORT | President & CEO | Feb 23, 2026 | Sell | $37.59 | 20,962 | $787,919.66 | 766,095 |
Compare AORT vs Leading Stocks
See how AORT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "AORT Artivion Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.